ACTICOR BIOTECH
Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million dies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It... is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. Acticor Biotech was founded in November 2013 and is headquartered in Paris, France.
ACTICOR BIOTECH
Industry:
Biopharma Biotechnology Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.acticor-biotech.com
Total Employee:
11+
Status:
Active
Contact:
+33970468640
Email Addresses:
[email protected]
Total Funding:
33.2 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Euro Microsoft Exchange Online
Similar Organizations
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Anaxago
Anaxago investment in Series B - Acticor Biotech
Newton Biocapital
Newton Biocapital investment in Series B - Acticor Biotech
A&B (HK)
A&B (HK) investment in Series B - Acticor Biotech
Karista
Karista investment in Series B - Acticor Biotech
Mirae Asset Global Investments
Mirae Asset Global Investments investment in Series B - Acticor Biotech
CMS Medical Venture Investment
CMS Medical Venture Investment investment in Series B - Acticor Biotech
GO CAPITAL
GO CAPITAL investment in Series B - Acticor Biotech
Mirae Capital
Mirae Capital investment in Series B - Acticor Biotech
Newton Biocapital
Newton Biocapital investment in Series B - Acticor Biotech
CMS Medical Venture Investment
CMS Medical Venture Investment investment in Series B - Acticor Biotech
Official Site Inspections
http://www.acticor-biotech.com Semrush global rank: 3.84 M Semrush visits lastest month: 3.42 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Acticor Biotech"
Acticor Biotech
GLENZOCIMAB, A FIRST-IN-CLASS DRUG FOR CARDIOVASCULAR EMERGENCIES . Acticor Biotech is a clinical stage biopharmaceutical company, spin-off from INSERM (French National Institute of Health and Medical …See details»
Team - Acticor Biotech
About us Acticor Team Board of Directors investors & Partners Prizes & Awards. Our Product. Our product: Glenzocimab GPVI / GLENZOCIMAB in brief in acute ischemic stroke in STEMI …See details»
Acticor Biotech - Crunchbase Company Profile & Funding
Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. …See details»
Acticor Biotech - LinkedIn
Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each …See details»
Acticor Biotech SAS Company Description - Stock Analysis
6 days ago Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops …See details»
Acticor Biotech Company Profile - Office Locations, Competitors
Acticor Biotech has 5 employees across 2 locations and $33.32 m in total funding,. See insights on Acticor Biotech including office locations, competitors, revenue, financials, executives, …See details»
Acticor Biotech - Contacts, Employees, Board Members
Organization. Acticor Biotech . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 6. ... Acticor …See details»
Acticor Biotech Liquidation Proceedings Announced
4 days ago Acticor Biotech, a clinical-stage biopharmaceutical company developing glenzocimab for cardiovascular emergencies, faces liquidation as the court-appointed administrator has …See details»
Acticor Biotech - Funding, Financials, Valuation & Investors
Acticor Biotech is registered under the ticker EPA:ALACT . Their stock opened with €7.12 in its Nov 1, 2021 IPO. Acticor Biotech is funded by 15 investors. UI Investissement and …See details»
Contact - Acticor Biotech
WHere to find Acticor Biotech. Contact information. You can contact us at [email protected] or +33 (0)6 76 23 38 13. Headquarter & Offices. Acticor Biotech SA Wojo Building …See details»
ACTICOR BIOTECH: Presentation of the Main Results of the Phase …
PARIS, May 15, 2024--Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an …See details»
Acticor Biotech SAS Statistics - Stock Analysis
6 days ago Acticor Biotech SAS has a market cap or net worth of EUR 3.92 million. The enterprise value is 6.35 million. Market Cap: 3.92M: Enterprise Value : 6.35M: Important …See details»
Acticor Biotech Updates Its Glenzocimab Clinical Development …
PARIS, June 03, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the …See details»
Acticor Biotech SAS (EPA: ALACT) - Stock Analysis
6 days ago Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops …See details»
Corporate Presentation - Acticor Biotech
→ Regulated Information. → Financial Information → Other Regulated Information → Governance → Financial Agenda → Contact Ask Us Your Questions Subscribe To Email AlertSee details»
Acticor Biotech Announces the Filing of a Request for Conversion …
5 days ago PARIS, December 10, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing …See details»
Acticor Biotech SAS Ratios and Metrics - Stock Analysis
6 days ago Acticor Biotech SAS Ratios and Metrics. Market cap in millions EUR. Fiscal year is January - December. Millions EUR. Fiscal year is Jan - Dec. Current. Millions. Data Source. …See details»
Acticor Biotechannonce le dépôt d’une requête de conversion de …
5 days ago Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), société de biopharmaceutique au stade clinique spécialisée dans le développement de médicaments …See details»
Investors - Home - Acticor Biotech
This focus makes ACTICOR a unique value in the stock market for our shareholders, and we will do everything we can to successfully meet the next stages of our developments. – Gilles …See details»
Acticor Biotech SAS Market Cap - Stock Analysis
6 days ago Since November 1, 2021, Acticor Biotech SAS's market cap has decreased from 74.35M to 3.92M, a decrease of -94.72%. That is a compound annual growth rate of -61.08%.See details»